Ascendis Pharma A/S

NASDAQ: ASND · Real-Time Price · USD
162.72
-0.85 (-0.52%)
At close: May 30, 2025, 3:59 PM
162.84
0.07%
After-hours: May 30, 2025, 04:44 PM EDT

Ascendis Pharma A/S Statistics

Share Statistics

Ascendis Pharma A/S has 60.37M shares outstanding. The number of shares has increased by 5.7% in one year.

Shares Outstanding 60.37M
Shares Change (YoY) 5.7%
Shares Change (QoQ) 0.14%
Owned by Institutions (%) 99.99%
Shares Floating n/a
Failed to Deliver (FTD) Shares 41
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 3.76M, so 6.21% of the outstanding shares have been sold short.

Short Interest 3.76M
Short % of Shares Out 6.21%
Short % of Float 7.47%
Short Ratio (days to cover) 6.13

Valuation Ratios

The PE ratio is -20.36 and the forward PE ratio is 90.39. Ascendis Pharma A/S's PEG ratio is 0.86.

PE Ratio -20.36
Forward PE 90.39
PS Ratio 21.17
Forward PS 3.1
PB Ratio -72.81
P/FCF Ratio -25.02
PEG Ratio 0.86
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ascendis Pharma A/S.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of -8.1.

Current Ratio 1.17
Quick Ratio 0.84
Debt / Equity -8.1
Debt / EBITDA -2.95
Debt / FCF -2.78
Interest Coverage -4.26

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $357,562.44
Profits Per Employee $-371,764.01
Employee Count 1,017
Asset Turnover 0.31
Inventory Turnover 0.15

Taxes

Income Tax 4.84M
Effective Tax Rate -1.3%

Stock Price Statistics

The stock price has increased by 20.44% in the last 52 weeks. The beta is 0.4, so Ascendis Pharma A/S's price volatility has been higher than the market average.

Beta 0.4
52-Week Price Change 20.44%
50-Day Moving Average 158.13
200-Day Moving Average 141.19
Relative Strength Index (RSI) 53.99
Average Volume (20 Days) 503,567

Income Statement

In the last 12 months, Ascendis Pharma A/S had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.

Revenue 363.64M
Gross Profit 319.38M
Operating Income -278.76M
Net Income -378.08M
EBITDA -290.02M
EBIT -307.74M
Earnings Per Share (EPS) -6.53
Full Income Statement

Balance Sheet

The company has 559.54M in cash and 856.62M in debt, giving a net cash position of -297.07M.

Cash & Cash Equivalents 559.54M
Total Debt 856.62M
Net Cash -297.07M
Retained Earnings n/a
Total Assets 1.06B
Working Capital 35.98M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -306.2M and capital expenditures -1.43M, giving a free cash flow of -307.62M.

Operating Cash Flow -306.2M
Capital Expenditures -1.43M
Free Cash Flow -307.62M
FCF Per Share -5.31
Full Cash Flow Statement

Margins

Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.

Gross Margin 87.83%
Operating Margin -76.66%
Pretax Margin -102.64%
Profit Margin -103.97%
EBITDA Margin -79.76%
EBIT Margin -76.66%
FCF Margin -84.6%

Dividends & Yields

ASND does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ASND is $207, which is 27.2% higher than the current price. The consensus rating is "Buy".

Price Target $207
Price Target Difference 27.2%
Analyst Consensus Buy
Analyst Count 15
Stock Forecasts

Scores

Altman Z-Score 4.21
Piotroski F-Score 2